Welcome!

News Feed Item

Concise Analysis of the International New Oral Anticoagulants Markets

DUBLIN, February 5, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/vgwhc9/new_oral) has announced the addition of the "Concise Analysis of the International New Oral Anticoagulants Markets" report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Anticoagulants decrease the ability of the blood to create harmful blood clots that can ultimately leading to a heart attack or stroke. Although sometimes referred to as blood thinners, they do not actually thin the blood and only help prevent the formation of new blood clots. For more than 50 years and until recently, the only oral anticoagulants were vitamin K antagonists such as warfarin. Pradaxa (dabigatran), Xarelto (rivaroxaban), Eliquis (apixaban) and other new oral anticoagulants have several advantages over warfarin, including no periodical laboratory monitoring and more predictable effects with fixed doses. 

This report provides a thorough overview of these and other new oral anticoagulants, their approved indications, drug profiles, pharmacokinetic parameters and the respective areas of market growth. The study also analyzes almost all of the companies known to be marketing, manufacturing or developing oral anticoagulant products in the U.S. and worldwide. Detailed tables and charts with sales forecasts and marketshare data are also included. 


Key Topics Covered: 

1. Introduction 

2. An Overview of Anticoagulants 

3. Selected Oral Anticoagulants 

4. A Brief Overview of Antiplatelets 

5. Coagulation Assays 

6. Disease Conditions Targeted by Anticoagulants 

7. Market Analysis: Anticoagulants 

8. Market for Antiplatelets 

9. Deals in Anti-Thrombotic Therapeutics Sector 

10. Utilization of Anticoagulants and Antiplatelets in the U.S. 

11. Selected Company Profiles 


Companies Mentioned:

  • 1 Varespladib/A-002
  • Activase (Altepase)
  • Aggrastat
  • Akers Biosciences, Inc.
  • Angiomax (Bivalirudin)
  • Anthera Pharmaceuticals, Inc.
  • Argatroban
  • AstraZeneca, PLC
  • Boehringer Ingelheim GmbH
  • Boehringer's Dedication to Innovation
  • Boehringer's Therapeutic Breakthrough
  • Brilinta (Ticagrelor)
  • Cipla Limited
  • Clinical Studies
  • Coronary Artery By-Pass Graft Surgery-Related Bleeding
  • Daiichi Sankyo Company Ltd.
  • Discontinuation of Effient
  • Effient (Daiichi Sankyo)
  • Eisai Co., Ltd.
  • Eli Lilly & Co
  • Elinogrel
  • Eliquis (Apixaban)
  • Fondaparinux
  • Fragmin
  • Genentech, Inc.
  • General Risk of Bleeding
  • GlaxoSmithKline PLC
  • Hypersensitivity Including Angiodema
  • Idrabiotaparinux
  • LIXIANA
  • Lovenox (Enoxaparin)
  • Medicure, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Ortho-McNeil Pharmaceutical, Inc.
  • PIFA Heparin/Platelet Factor 4 Rapid Assay
  • Pfizer, Inc.
  • Pharmion, LLC
  • Portola Pharmaceuticals, Inc.
  • RYx Therapeutics, Inc.
  • Registration Study RE-LY
  • Rivaroxaban (Xarelto)
  • SCH 5303348
  • Sanofi
  • Tecarfarin
  • Tecarfarin Development Status
  • The Medicines Company
  • Thrombotic Thrombocytopenic Purpura
  • Tinzaparin (Innohep)


For more information visit http://www.researchandmarkets.com/research/vgwhc9/new_oral


Media Contact: Laura Wood, +353-1-481-1716, [email protected]


SOURCE Research and Markets

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In this presentation, you will learn first hand what works and what doesn't while architecting and deploying OpenStack. Some of the topics will include:- best practices for creating repeatable deployments of OpenStack- multi-site considerations- how to customize OpenStack to integrate with your existing systems and security best practices.
"MobiDev is a software development company and we do complex, custom software development for everybody from entrepreneurs to large enterprises," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Agile has finally jumped the technology shark, expanding outside the software world. Enterprises are now increasingly adopting Agile practices across their organizations in order to successfully navigate the disruptive waters that threaten to drown them. In our quest for establishing change as a core competency in our organizations, this business-centric notion of Agile is an essential component of Agile Digital Transformation. In the years since the publication of the Agile Manifesto, the conn...
"We work around really protecting the confidentiality of information, and by doing so we've developed implementations of encryption through a patented process that is known as superencipherment," explained Richard Blech, CEO of Secure Channels Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Major trends and emerging technologies – from virtual reality and IoT, to Big Data and algorithms – are helping organizations innovate in the digital era. However, to create real business value, IT must think beyond the ‘what’ of digital transformation to the ‘how’ to harness emerging trends, innovation and disruption. Architecture is the key that underpins and ties all these efforts together. In the digital age, it’s important to invest in architecture, extend the enterprise footprint to the cl...
Leading companies, from the Global Fortune 500 to the smallest companies, are adopting hybrid cloud as the path to business advantage. Hybrid cloud depends on cloud services and on-premises infrastructure working in unison. Successful implementations require new levels of data mobility, enabled by an automated and seamless flow across on-premises and cloud resources. In his general session at 21st Cloud Expo, Greg Tevis, an IBM Storage Software Technical Strategist and Customer Solution Architec...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, discussed the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
"We were founded in 2003 and the way we were founded was about good backup and good disaster recovery for our clients, and for the last 20 years we've been pretty consistent with that," noted Marc Malafronte, Territory Manager at StorageCraft, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Effectively SMBs and government programs must address compounded regulatory compliance requirements. The most recent are Controlled Unclassified Information and the EU's GDPR have Board Level implications. Managing sensitive data protection will likely result in acquisition criteria, demonstration requests and new requirements. Developers, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by incorporating changes. In...
Two weeks ago (November 3-5), I attended the Cloud Expo Silicon Valley as a speaker, where I presented on the security and privacy due diligence requirements for cloud solutions. Cloud security is a topical issue for every CIO, CISO, and technology buyer. Decision-makers are always looking for insights on how to mitigate the security risks of implementing and using cloud solutions. Based on the presentation topics covered at the conference, as well as the general discussions heard between sessio...
IoT is rapidly becoming mainstream as more and more investments are made into the platforms and technology. As this movement continues to expand and gain momentum it creates a massive wall of noise that can be difficult to sift through. Unfortunately, this inevitably makes IoT less approachable for people to get started with and can hamper efforts to integrate this key technology into your own portfolio. There are so many connected products already in place today with many hundreds more on the h...
Andi Mann, Chief Technology Advocate at Splunk, is an accomplished digital business executive with extensive global expertise as a strategist, technologist, innovator, marketer, and communicator. For over 30 years across five continents, he has built success with Fortune 500 corporations, vendors, governments, and as a leading research analyst and consultant.
No hype cycles or predictions of zillions of things here. IoT is big. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, Associate Partner at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He discussed the evaluation of communication standards and IoT messaging protocols, data analytics considerations, edge-to-cloud tec...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Announcing Poland #DigitalTransformation Pavilion